Main Article Content



Metabolic Syndrome is a constellation of cardio metabolic abnormalities such as central obesity, dyslipidemia, hyperglycemia, hypertension, proinflammatory and prothrombotic state. Dyslipidemia is one of the important components of this syndrome and also important risk factor for cardiovascular disease. Statins are used as first line drugs for dyslipidemia but right now several drugs are available in Indian market and it is difficult for medical practitioners to select a suitable one among them. This is a study to evaluate the efficacy and safety of most commonly used atorvastatin with rosuvastatin in patients with metabolic syndrome.


To compare the efficacy and safety of Rosuvastatin and Atorvastatin in patients with metabolic syndrome.


A total of 60 subjects diagnosed with Metabolic syndrome were included in the study. They were randomized into two groups, the first group received, Rosuvastatin 10mg and second group received Atorvastatin 10 mg for 6 weeks. Lipid profile was evaluated for efficacy; liver function tests (LFT) and serum creatine for safety. Adverse effects were evaluated based on symptomatology and laboratory parameters.


Both the groups showed significant improvement in lipid profile, seen by reduction in LDL, Triglycerides, total cholesterol and increase in HDL levels compared to baseline values (p<0.001). Intergroup comparison showed that 10mg of Rosuvastatin was better in providing a favourable lipid profile compared to 10mg of Atorvastatin. Changes in LFT and serum creatine were not significant statistically both within and between the groups.


Rosuvastatin was found to be better than atorvastatin in providing a favourable lipid profile for patients with metabolic syndrome and both the drugs were well tolerated and safe.


Metabolic syndrome dyslipidemia atorvastatin rosuvastatin

Article Details

How to Cite
Dr Sushma H K, & Dr Jyothi C H. (2021). Comparative study on efficacy and safety of Rosuvastatin v/s Atorvastatin in patients with metabolic syndrome- a prospective observational study. International Journal of Research in Pharmacology & Pharmacotherapeutics, 8(3), 326-334.


  1. [1]. Robert HE. The metabolic syndrome,In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et al, editors. “Harrison’s Principles of internal medicine”.18th edition. New York :McGraw Hill. 2012, 1992- 1997.
  2. [2]. Scott MG, James IC, Stephen RD, Karen AD, Robert HE, Barry AF. Diagnosis and management of the metabolic syndrome. Circulation 112, 2005, 2735-52.
  3. [3]. Steven A, Ben Lacey, Premila W, Mike R, Mohan D, Peter S et al. Level of urbanization and non communicable disease risk factors in Tamil nadu, India. Bulletin of WHO. 88, 2010, 297-304. doi: 10.2471/BLT.09.065847.
  4. [4]. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. JACC 15, 2011, 57(11) :1299–313.
  5. [5]. Bruce KD, Mark AH. The Developmental Origins, Mechanisms and Implications of Metabolic Syndrome.
  6. [6]. Simmons RK, Alberti KGMM, Gale EAM, Colagiuri S, Tuomilehto J, Qiao Q et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53, 2010, 600–605.
  7. [7]. Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS et al .Comparative study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia. The Korean Journal of Internal Medicine 25(1), 2010, 27-35.
  8. [8]. United Nations (2008) The Millennium Development Goals report 2008. United Nations, New York.
  9. [9]. Pitsavos C, Panagiotakos D, Weinem M, Stefanadis C. Diet, exercise and the metabolic syndrome. Rev Diabet Stud 3, 2006, 118 –26.
  10. [10]. Bersot TP. Drug therapy for Hypercholesteremia and Dyslipidemia.In;Bruton LL, Chabner BA, KnollmannBC,Editors. Goodman and Gillman’s “The pharmacological Basis of Theurapeutics”.12th ed. New Delhi: McGraw hill;2011, 877-908.
  11. [11]. Dimmeler S, Adler K, Martin H, Aicher A, Tiemann M, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. The Journal of Clinical Investigation 108(3), 2001, 391-397.
  12. [12]. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 19, 1996, 348: 1079–82.
  13. [13]. Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H et al. A Comparative Study With rosuvastatin in subjects with Metabolic Syndrome: results of the COMETS study. European Heart Journal 26, 2005, 2664-2672.
  14. [14]. Sharma HL, Sharma KK. “Principles of Pharmacology”. 2nd ed. Hyderabad: Paras Medical Publisher;2011, 324-335.
  15. [15]. Tripathi KD. “Essentials of Medical Pharmacology”. 6th ed. New Delhi: Jaypee Medical Publishers (pvt) ltd;2008, 612-623.
  16. [16]. Alvin Jose M, Anandkumar S, Narmada MP, Sandeep M. A Comparative effect of atorvastatin with other statins in patients of hyperlipidemia. Indian Journal of Pharmacology 44(2), 2012, 261-263.
  17. [17]. Abbas A, Milles J, Ramachandran S. Rosuvastatin and Atorvastatin: Comparative Effects On Glucose Metabolism in Non-Diabetic Patients with Dyslipidemia. Clinical Medicine Insights: Endocrinology and Diabetes 5, 2012, 13-30.
  18. [18]. MClearfield MB, Amerena J, Bassand JP, Hernández García HR, Miller SS, Sosef FFM. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia– Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials Journal 7, 2006, 35.
  19. [19]. Strandberg TE, Feely J, Sigurdsson EL. Twelve-Week, Multicenter, Randomized, Open-Label Cornparison of the Effects of Rosuvastatin I 0 mg/d and Atorvastatin I 0 mg/d in High-Risk Adults: A DISCOVERY Study. Clinical therapeutics 26(11), 2004, 1821-1833.
  20. [20]. Berne C, Delle AS, et al. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology 2005, 4(7).
  21. [21]. Adsule SM, Baig MS, Gade PR, Khandelwal PN. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. IntDiabDevCtries 29(2)2009, 74-79.
  22. [22]. Sindhu S, Singh HK, Salmaan MT, Fatima J, Verma VK. Effects of atorvastatin and rosuvastatin on high sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. Journal of Pharmacology and Pharmacotherapeutics 2(4), 2011, 261-265.
  23. [23]. Schwartz GG, Hutchinson H, Bolognese MA, Raza A, Tremblay BP,lCressman M, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. American Heart Journal 2004, 148(1).
  24. [24]. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). The American Journal of Cardiology 15(93), 2003, 152- 160.
  25. [25]. Berry DA , Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J. 145(6), 2003, 1036-45.
  26. [26]. BullanoMF , Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 26(4), 2006, 469-78.
  27. [27]. OhsfeldtRL , Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 12(15), 2006, S412-23.
  28. [28]. Schwartz GG , Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 148(1), 2004, 4.
  29. [29]. Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J GeriatrPharmacother.5(3), 2007, 185-94.
  30. [30]. Fonseca FA, Ruiz A, Cardona-Munoz EG, Silva JM, Fuenmayor N, Marotti M, et al. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of RosuvastatintherapY compared with atorvastatin. Curr Med Res Opin. 21(8), 2005, 1307-15.
  31. [31]. StrandbergTE , Feely J, Sigurdsson EL, et al. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. ClinTher. 26(11), 2004, 1821-33.
  32. [32]. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 8, 350(15), 2004, 1495-1504.
  33. [33]. Rao AD, Milbrandt EB. To JUPITER and beyond: Statins, inflammation, and primary prevention. Critical Care 14(3), 2010, 310.
  34. [34]. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovascular Research 86, 2010, 311–320.